BNP PARIBAS ARBITRAGE/PUT/MODERNA/150/0.1/20.12.24 | Market Closed - Euronext Paris 10:00:01 05/07/2024 pm IST | ||
| 3.715 EUR | +3.63% |
|
| Current month | +3.96% | ||
| 1 month | +66.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 05/24/05 | 3.675 | +2.51% |
| 04/24/04 | 3.585 | -5.03% |
| 03/24/03 | 3.775 | 0.00% |
| 02/24/02 | 3.775 | +0.80% |
| 01/24/01 | 3.745 | +5.94% |
Real-time Euronext Paris
Last update July 05, 2024 at 10:00 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| 8HOOB | |
| ISIN | NLBNPFR20R30 |
| Date issued | 28/05/2024 |
| Strike | 150 $ |
| Maturity | 20/12/2024 (167 Days) |
| Parity | 10 : 1 |
| Emission price | 1.39 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.895 € |
|---|---|
| Lowest since issue | 1.775 € |
| Spread | 0.01 € |
| Spread % | 0.27% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.3
USD
Average target price
145.9
USD
Spread / Average Target
+23.27%
- Stock Market
- Warrants
- 8HOOB Warrant
